Adicet Bio Inc
Company Profile
Business description
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.
Contact
131 Dartmouth Street
3rd Floor
BostonMA02116
USAT: +1 650 503-9095
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
152
Stocks News & Analysis
stocks
Qantas earnings: Jetstar capitalising on weaker domestic competition
stocks
Nvidia Earnings: No signs of a slowdown in demand for AI chips
stocks
ASX results reaction: WiseTech, Woolies, Sigma and more
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,243.00 | 9.00 | 0.10% |
CAC 40 | 7,703.90 | 58.70 | -0.76% |
DAX 40 | 23,902.21 | 137.71 | -0.57% |
Dow JONES (US) | 45,544.88 | 92.02 | -0.20% |
FTSE 100 | 9,187.34 | 29.48 | -0.32% |
HKSE | 25,077.62 | 78.80 | 0.32% |
NASDAQ | 21,455.55 | 249.61 | -1.15% |
Nikkei 225 | 42,718.47 | 110.32 | -0.26% |
NZX 50 Index | 12,930.73 | 27.65 | 0.21% |
S&P 500 | 6,460.26 | 41.60 | -0.64% |
S&P/ASX 200 | 8,973.10 | 4.10 | 0.05% |
SSE Composite Index | 3,857.93 | 14.33 | 0.37% |